Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG) - Agnieszka Pluta, Tadeusz Robak, Kamil Brzozowski, Konrad Stepka, Ewa Wawrzyniak, Anna Krawczynska, Magdalena Czemerska, Anna Szmigielska-Kaplon, Olga Grzybowska-Izydorczyk, Mateusz Nowicki, Piotr Stelmach, Marta Kuydowicz, Tomasz Gromek, Marek Hus, Grzegorz Helbig - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Taylor and Francis Group, Leukemia & Lymphoma, 3(61), p. 588-603, 2019

DOI: 10.1080/10428194.2019.1678151

Links

Tools

Export citation

Search in Google Scholar

Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG)

Journal article published in 2019 by Agnieszka Pluta, Tadeusz Robak, Kamil Brzozowski, Konrad Stepka, Ewa Wawrzyniak, Anna Krawczynska, Magdalena Czemerska, Anna Szmigielska-Kaplon, Olga Grzybowska-Izydorczyk, Mateusz Nowicki, Piotr Stelmach, Marta Kuydowicz, Tomasz Gromek, Marek Hus, Grzegorz Helbig and other authors.

Distributing this paper is prohibited by the publisher

Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle

Preprint: archiving forbidden

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO